GenePOC will participate in the ASM (American Society for Microbiology) from June 7 to 11, in Atlanta, USA. Come visit our booth #1420 – Discover the power of the PIE and revogene instrument for molecular detection of infectious diseases.
This author has yet to write their bio.Meanwhile lets just say that we are proud email@example.com contributed a whooping 33 entries.
Entries by firstname.lastname@example.org
Practical Patient Care talks to Dr Mayra Bermudez Martinez, an obstetrician in the Klinik für Gynäkologie und Geburtshilfe at the Hochst Klinikum in Frankfurt, about the importance of timely screening for Group B Streptococcus in infants. Read the entire article here.
GenePOC will participate in the 28th ECCMID (European Congress of Clinical Microbiology and Infectious Diseases) from April 21 to 24, in Madrid, Spain. Come visit our booth #40 – Discover the power of the PIE and revogene instrument for molecular detection of infectious diseases. Don’t miss our symposium on Monday 23rd – Hall J – […]
Under the terms of the services agreement, Primerdesign will develop a triplex molecular diagnostic assay to identify influenza A, influenza B and respiratory syncytial virus A and B (RSV A and B) which will subsequently be run on GenePOC’s revogene™ instrument. Full article : here
Clostridium difficile infection (CDI) is the main cause of infectious antibiotic-associated diarrhea with approximately 500,000 infections and $4.8 billion in excess healthcare cost per year in the US1. While diagnosis of C. difficile still remains controversial worldwide, the new IDSA guidelines reaffirm that PCR is the most sensitive method for toxigenic C. difficile detection. Find here […]
GenePOC at the heart of POC testing for infectious diseases – Yole’s MedTech experts Sebastien Clerc and Asma Siari, recently had the opportunity to interview our CEO – Patrice Allibert. They mention GenePOC as one of the field’s key players in molecular diagnostics at point-of-care (POC). Read the entire article here.
GenePOC announces it received clearance from Health Canada for GenePOC™ GBS LB test and its revogene™ instrument. Read the Press Release
GenePOC announces it received 510(k) clearance from the US Food and Drug Administration to market its second molecular assay to detect toxigenic Clostridium difficile. Read the Press Release
GenePOC has received the CE marking for its third bacteriological test, GenePOC GBS DS, for the direct screening of Group B Streptococcus at intrapartum . Read the entire Press Release her.
GenePOC will participate in the AMP from November 16 to 18, in Salt Lake City, UT, USA. Come visit our booth #1028 , and discover the revogene system for cost-effective, rapid, and accurate molecular detection of infectious diseases at Point-of-Care
Contact UsIf you have questions, comments or need more information concerning GenePOC, talk to one of our customer service representatives. We will be pleased to assist you.
Write360 Rue Franquet, Porte 3
Canada G1P 4N3
Call1 (418) 650-3535
Monday to Friday
8:00 a.m. to 5:00 p.m. EST